Tianjin Lisheng Pharmaceutical Co.,Ltd. (SHE:002393)
China · Delayed Price · Currency is CNY 14.30
+0.01 (0.07%)
Jul 30, 2026, 10:55 AM CST
SHE:002393 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,403 | 5,562 | 4,511 | 4,810 | 3,917 | 3,943 | |
Market Cap Growth | -27.72% | 23.28% | -6.20% | 22.78% | -0.65% | 5.98% |
Enterprise Value | 1,999 | 3,591 | 2,366 | 2,736 | 2,491 | 2,354 |
Last Close Price | 14.29 | 17.35 | 13.80 | 14.24 | 11.47 | 11.48 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 10.63 | 13.36 | 24.45 | 13.29 | 41.85 | 32.29 |
Forward PE | - | 18.18 | 18.18 | 18.18 | 18.18 | 18.18 |
PS Ratio | 3.25 | 4.00 | 3.38 | 4.17 | 3.42 | 3.61 |
PB Ratio | 0.95 | 1.19 | 0.94 | 0.98 | 0.90 | 0.89 |
P/TBV Ratio | 1.00 | 1.26 | 1.00 | 1.01 | 0.93 | 0.92 |
P/FCF Ratio | 20.51 | 26.48 | 130.72 | 34.78 | 13.49 | 36.48 |
P/OCF Ratio | 17.65 | 22.47 | 51.11 | 24.05 | 11.82 | 20.08 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.48 | 2.58 | 1.77 | 2.37 | 2.17 | 2.16 |
EV/EBITDA Ratio | 10.78 | 21.50 | 16.02 | 14.79 | 19.73 | 26.77 |
EV/EBIT Ratio | 18.35 | 38.42 | 34.08 | 23.07 | 40.80 | 82.13 |
EV/FCF Ratio | 9.31 | 17.10 | 68.54 | 19.79 | 8.57 | 21.78 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.24 | 0.27 | 0.34 | 0.18 | 0.35 | 0.39 |
Debt / FCF Ratio | 0.21 | 0.22 | 1.48 | 0.24 | 0.16 | 0.32 |
Net Debt / Equity Ratio | -0.53 | -0.54 | -0.48 | -0.45 | -0.45 | -0.37 |
Net Debt / EBITDA Ratio | -13.45 | -15.04 | -15.70 | -11.82 | -15.43 | -18.39 |
Net Debt / FCF Ratio | -11.36 | -11.96 | -67.17 | -15.81 | -6.71 | -14.96 |
Asset Turnover | 0.24 | 0.25 | 0.23 | 0.21 | 0.22 | 0.21 |
Inventory Turnover | 2.85 | 2.94 | 3.12 | 2.60 | 2.39 | 2.03 |
Quick Ratio | 4.17 | 4.06 | 3.75 | 4.05 | 3.28 | 3.75 |
Current Ratio | 4.52 | 4.37 | 4.10 | 4.50 | 3.60 | 4.26 |
Return on Equity (ROE) | 8.86% | 8.94% | 3.83% | 7.82% | 2.14% | 2.80% |
Return on Assets (ROA) | 1.20% | 1.03% | 0.75% | 1.34% | 0.73% | 0.35% |
Return on Invested Capital (ROIC) | 4.66% | 3.75% | 2.30% | 3.99% | 1.86% | 0.92% |
Return on Capital Employed (ROCE) | 2.30% | 1.90% | 1.40% | 2.30% | 1.30% | 0.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 9.38% | 7.49% | 4.09% | 7.52% | 2.39% | 3.10% |
FCF Yield | 4.88% | 3.78% | 0.77% | 2.88% | 7.41% | 2.74% |
Dividend Yield | 7.15% | 4.32% | 2.11% | 2.51% | 1.56% | 1.56% |
Payout Ratio | 41.91% | 23.30% | 65.59% | 15.13% | 58.48% | 14.94% |
Buyback Yield / Dilution | 0.70% | -0.26% | 0.83% | -0.59% | -0.70% | -5.91% |
Total Shareholder Return | 7.85% | 4.06% | 2.95% | 1.92% | 0.86% | -4.35% |